Aficamten Outperforms Metoprolol in Treating Obstructive Hypertrophic Cardiomyopathy
Table of Contents
Aficamten treatment demonstrated significant improvements in exercise capacity and symptom relief compared to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM),according to research presented at ESC Congress 2025 and published in the New England Journal of Medicine.
Current Treatment Landscape for Obstructive HCM
Beta-blockers are frequently used to manage symptoms in patients with obstructive HCM. However, they don’t address the root cause of the disease and their effectiveness is questionable. Aficamten, a cardiac myosin inhibitor, directly targets the hypercontractility characteristic of obstructive HCM.
The Aficamten vs.Metoprolol Study
A recent phase III trial showed aficamten improved peak oxygen uptake compared to placebo in patients who continued to experience symptoms despite being on beta-blockers. This new research directly compared aficamten to metoprolol as a first-line treatment option.
Key Findings
- Aficamten led to greater improvements in exercise capacity compared to metoprolol.
- Patients treated with aficamten reported a more significant reduction in symptoms.
- The study suggests aficamten may be a superior alternative to beta-blockers for managing obstructive HCM.
How Aficamten Works
Aficamten works by selectively inhibiting cardiac myosin, the protein responsible for muscle contraction in the heart. By reducing the force of contraction, aficamten helps to alleviate the obstruction in the left ventricular outflow tract, improving blood flow and reducing symptoms.
Benefits of Targeting Hypercontractility
Addressing the underlying hypercontractility offers several potential advantages over customary symptom management with beta-blockers:
- More direct impact on the disease mechanism.
- Potential for greater symptom relief.
- Improved exercise capacity and quality of life.
Future Implications
These findings suggest that aficamten could become a new standard of care for patients with symptomatic obstructive HCM. Further research is needed to determine the long-term effects of aficamten and to identify the patients who are most likely to benefit from this treatment.
FAQ
Q: What is obstructive hypertrophic cardiomyopathy (HCM)?
A: HCM is a condition where the heart muscle becomes abnormally thick, leading to an obstruction of blood flow from the left ventricle.
Q: How does aficamten differ from beta-blockers?
A: Beta-blockers manage symptoms by slowing the heart rate and reducing blood pressure. Aficamten directly addresses the underlying cause of obstruction by reducing the force of heart muscle contraction.
Q: Is aficamten suitable for all HCM patients?
A: Aficamten is specifically indicated for patients with symptomatic obstructive HCM. It’s important to discuss treatment options with a cardiologist.
publication Date: 2025/09/01 18:58:46